Crosser Enters The Right Arterial Lumen — CENTRAL  

Chronic Total Occlusion of Artery of the Extremities Clinical Trial

Official title: Crosser Enters The Right Arterial Lumen

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if the CROSSER CTO Recanalization System can facilitate the successful crossing of Chronic Total Occlusions in the Central lumen of the Superficial Femoral Artery (SFA). A Chronic Total Occlusion (CTO) is defined as 100% narrowing of the artery, with no angiographically detectable antegrade blood flow, and the assessment that the lesion has been in existence for a minimum of 30 days. This study will enroll up to 100 patients at up to 8 clinical sites. The CROSSER CTO Recanalization System was cleared for commercialization by the US Food & Drug Administration. This study also involves an imaging device called the IVUS (Intravascular Ultrasound Imaging) catheter. This device has been cleared for commercialization by the US Food and Drug Administration and will be studied for its cleared intended use. The IVUS catheter is used to generate real-time images of the artery, which will allow for evaluation of the artery after the occlusion is crossed. This is a post-market registry.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chronic Total Occlusion of Artery of the Extremities

• NCT number: NCT01205386
• Study type: Observational
• Source: C. R. Bard
• Status: Completed
• Phase: N/A
• Start date: February 2010
• Completion date: August 2012